Contact A Lawyer
Have A Potential Case Reviewed By An Attorney
Following an MRI, side effects of gadolinium contrast agents used to enhance the scans may result in the development of a painful and debilitating medical condition, known as Gadolinium Deposition Disease (GDD). This has left patients suffering severe headaches, joint pain, loss of mobility, loss of cognitive function and other complications.
GADOLINIUM DEPOSITION DISEASE LAWSUITS: Lawyers are reviewing potential MRI gadolinium lawsuits for individuals who have experienced problems like:
- Brain Fog or Memory Impairment
- Persistent Headache
- Burning Sensation of the Skin
- Joint or Bone Pain
- Skin Discoloration or Thickening
- Feelings of Pins and Needles, Burning or Cutting Pain in the Arms, Legs or Body
MRI CONTRAST DYE: This condition may result from the use of certain gadolinium-based contrast agents, including Magnevist, MultiHance, Omniscan; OptiMARK; ProHance, Gadavist and others.
OVERVIEW: Gadolinium is a highly toxic heavy metal, which is used as a contrast agent during MRI and MRA exams. The dye is administered to enhance images, but studies have found that individuals may experience a buildup of gadolinium in the brain and body, which reports suggest may have devastating side effects.
In 2007, the use of gadolinium contrast agents was restricted for individuals with kidney problems, due to the risk of a painful and life-threatening condition known as nephrogenic systemic firbosis (NSF), which causes a thickening and hardening of the skin that progressively restricts movement, ultimately resulting in the need for a wheelchair and premature death.
However, recent reports suggest that gadolinium MRI contrast agents pose serious risks even for individuals without kidney problems.
GADOLINIUM DEPOSITION DISEASE (GDD): Gadolinium does not naturally occur in the body, and MRI or MRA contrast agents are the only known causes for the buildup of this toxic heavy metal in the brain and body.
Gadolinium deposition disease (GDD) is a medical condition describing individuals with normal kidney function who develop persistent symptoms within hours or weeks after an MRI with contrast. Typical complaints may include persistent headaches, bone and joint pain, clouded mental activity, pain in the arms and legs and other symptoms.
This condition is progressive and there is no cure, often resulting in the painful inability to use the arms, legs, hands, feet or other joints.
The condition was first defined in an August 2016 study published in Magnetic Resonance Imaging, by researchers from the University of North Carolina. The findings indicate that GDD can occur after a single injection of gadolinium-based MRI dyes.
In December 2017, the FDA announced new MRI contrast dye warnings about the risk of gadolinium building up in the body, urging doctors to consider this factor when deciding whether to give a gadolinium injection to patients, especially when MRI exams are scheduled close together.
A growing number of lawsuits over gadoliniun deposition disease are now being pursued in courts nationwide, alleging that the manufacturers knew or should have known about the risks, yet withheld important warnings from consumers and the medical community.
PRIOR GADOLINIUM SETTLEMENTS: The recent cases come after the manufacturers previously agreed to pay millions in gadolinium settlements for individuals diagnosed with nephrogenic systemic fibrosis (NSF).
Some of the symptoms of Gadolinium Deposition Disease appear to be very similar to NSF, which can cause excessive formation of connective tissues in the skin and organs, resulting in tissue thickening and hardening, particularly in the skin, and on the limbs and trunk. It can severely limit movement of the joints, causes severe pain and can lead to death in some cases.
In recent years, the risk of NSF has largely been avoided by not using gadolinium contrast agents among individuals with kidney problems, highlighting the importance of warnings provided by the manufacturers.
CONTACT A GADOLINIUM DEPOSITION DISEASE LAWYER: As a result of the manufacturers’ failure to thoroughly research the effects of gadolinium on the body, and their failure to provide adequate warnings about the risk of gadolinium building up in the bodies of individuals with normal kidney functions, financial compensation may be available through a Gadolinium Deposition Disease lawsuit.
If warnings and information about the risk of gadolinium injections had been provided, many patients may not have chosen to receive the dyes, and some cases of gadolinium injuries may have been avoided.